Product Overview
Generic Peptides offers PNC-27 as a 5 mg lyophilised vial. It is a research material in the strict sense of the phrase, because everything known about the molecule comes from work in cultured cells and animal models. There is no approved pharmaceutical form, no clinical programme and no schedule that a supplier could quote from a label. Buyers should approach the page with that framing in mind.
The peptide is chimeric, built from two joined parts. One is a stretch of the p53 protein covering residues 12 to 26, the domain that recognises HDM-2, also written MDM2. The other is a membrane-penetrating sequence that lets the molecule cross a lipid bilayer. Joined together, the 32 residue construct is designed to recognise HDM-2 in places a plain p53 fragment would not reach, including the outer surface of tumour cells in culture.
PNC-27 is not a steroid, not a hormone and not a growth peptide. It shares nothing with the recovery compounds in this catalogue except the vial format. Products that sit on the same research shelf in the immune and repair section are Thymosin Alpha-1, BPC-157 and Thymalin, all of which have their own evidence bases and their own limits. Nothing on this page describes a treatment, and nothing here should be read as one.
Preclinical Status and Dilution
Because no human dose exists, this table carries laboratory status and reconstitution arithmetic only. The numbers describe how a 5 mg vial is divided, not how much anyone should take.
| Item | Figure | Comment |
| Human dose | None exists | No phase I, II or III work and no recommended amount in any source |
| Half-life | Not established | No human pharmacokinetic study was located, so no figure can be quoted honestly |
| 5 mg plus 1 ml | 5 mg per ml | 1 mg is 0.2 ml, or 20 units on a U-100 barrel; 500 mcg is 0.1 ml, or 10 units |
| 5 mg plus 2 ml | 2.5 mg per ml | 1 mg is 0.4 ml, or 40 units; microgram steps need a low-volume barrel |
| Solvent | Bacteriostatic water | Added down the wall of the vial and swirled, never shaken |
| Storage | 2-8 C, dark | The dry cake keeps far longer in a freezer; a mixed vial holds about 28 days chilled |
| Regulatory standard | None | No pharmacopoeia monograph covers this peptide, so purity claims rest on the supplier |
Two points deserve emphasis. First, a concentration table is not a dosing table: it tells a laboratory how to deliver a defined quantity of material into a dish, and it says nothing about what quantity is acceptable in a living person. Second, with no monograph and no regulator, the practical variable a buyer can control is the source, which is why batch documentation matters more here than on any steroid page in the catalogue.
Laboratory Study Layouts
There is no protocol to reproduce, because the studies that exist are bench experiments. What follows is a reading of the current work rather than a set of routines.
Where a laboratory is assembling a general research shelf, NAD+ covers cellular energy metabolism and Selank and Semax cover the neuropeptide side. None of those is a partner for this peptide in any published work, and the pairing of compounds on a shelf is not evidence of anything.
What to Expect in Preclinical Work
- A mechanism, not a result. The peptide folds into a shape that binds HDM-2, which in culture is found on the surface of cancer cells as well as inside them.
- Membrane pores and cell death. Binding is followed by the formation of pores across the membrane and necrosis of the cell in culture.
- Selectivity reported in a dish. In cell culture the construct lysed cancer cells while leaving healthy cells intact, a difference attributed to those membrane HDM-2 complexes.
- No human data of any kind. No controlled study in people, no dose finding, no safety record. That is the whole of the human evidence base.
- No approval anywhere in the world. This is a laboratory reagent, and it has never been licensed for any use in medicine.
- A regulator has issued a warning. Authorities cautioned consumers against products marketed under this name as a cancer treatment, and a contaminating bacterium was found in a sample of an inhaled solution.
- Contamination is a real risk on this shelf. Products offered without documented sterility testing are the practical hazard that a buyer can actually do something about.
Side Effects and Management
There is no human safety database for this compound, so the honest position is that unknown effects cannot be listed as rare, common or absent. What follows is a statement of the gaps and the laboratory-level precautions.
Regulatory Position and What Replaces a PCT
This peptide has no relationship to the hormonal axis. It does not suppress testosterone production, so a restart protocol is irrelevant here, and no dose of tamoxifen or clomiphene would do anything about the risks that do exist.
Anyone reading this card looking for a cancer treatment has arrived at the wrong page, and the sources are unanimous on that point. The material is sold for laboratory investigation, the mechanism is still being characterised in culture, and the responsible position for a supplier is to state the gaps rather than paper over them with a number that does not exist.
